An observational study in Fracture, sponsored by University Hospital, Montpellier. Status unknown at 1 site in France. Open to participants aged 0 Years to 2 Years. Per ClinicalTrials.gov, last updated 2022-09-13.
Sponsored by University Hospital, Montpellier · Observational
The artificial intelligence (AI) software BoneView (GLEAMER Company, Paris, France) has been designed, tested and validated to detect and locate recent or semi-recent fractures on standard radiographs.
The objective will be to assess the AI performance for the detection of bone fractures in children aged less than 2 years old in suspected child abuse setting.
These patients benefit from a whole body radiography with a double blind reading by a "generalist" radiologist and a radiologist with expertise in child abuse. This readings will be compared with the AI results.
Hypothesis is that AI is effective for child fractures detection and could be of help especially for radiologists who are not experts in child abuse.
2,272 studies on the registry are indexed under Fractures, Bone; 321 are open to participants now.
This study's planned enrollment of 210 is above the median of 100 across 677 observational studies indexed under Fractures, Bone.
Browse Fractures, Bone studies →University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 227 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children aged less than 2 years old in suspected child abuse setting
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Percentage of fracture detected by AI on radiographs
Percentage of fracture detected by AI on radiographs
Time frame: 1 day
Plan to share: Undecided — NC
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Nov 2022, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →